In a letter to the Institute for Clinical and Economic Review (ICER), PIPC submitted comments on ICER's assessment of treatments for Metachromatic Leukodystrophy (MLD). |
"MLD is a rare hereditary disease for which there is no cure and very limited options for supportive care," wrote PIPC Chair Tony Coelho. "Treatments for this rare disease are urgently needed, and it is imperative that ICER consider the rare patient population and severity of the disease in its assessment."

icer_mld_final_for_submission_.pdf |